Research Protocol

 
News Articles for Research Protocol top ^
2014/1/23
MSCI Inc. (NYSE:MSCI), a leading provider of investment decision support tools worldwide, today announced that Kepos Capital L.P. (Kepos Capital) has selected MSCI for Open Protocol reporting, an industry wide risk reporting initiative.
Sign-up for Kepos Capital Selects MSCI for Open Protocol Reporting investment picks
2013/9/26
Support for EtherNet/IP in addition to PROFIBUS and EtherCAT enables OEMs to connect their devices to a wider range of PLCs or HMI systems DALLAS , Sept.
Sign-up for TI Sitara™ AM335x industrial software development kit supports new protocol, enhancing flexibility in industrial automation applications investment picks
2013/10/8
Voip-Pal.com Inc. (“Voip-Pal”, “Company”) (OTC Pink: VPLM) is pleased to announce that the US Patent and Trademark Office (USPTO) has allowed its patent application “Uninterrupted Transmission of Internet Protocol Transmissions During Endpoint Changes.” Allowance means that prosecution is closed for the patent application and it is allowed for issuance as a patent.
Sign-up for Voip-Pal.com Inc.’s Patent Application for Uninterrupted Transmission for Internet Protocol Receives Allowance for Issuance as a Patent investment picks
2014/2/3
Liberty Global plc (“Liberty Global”) (NASDAQ: LBTYA, LBTYB and LBTYK) filed with the U.S. Securities and Exchange Commission (“SEC”) a Form 8-K on January 31, 2014 with a copy of the merger protocol entered into between Liberty Global and Ziggo N.V. (“Ziggo”) on January 27, 2014.
Sign-up for Liberty Global Announces Filing of Merger Protocol investment picks
2014/2/13
Voip-Pal.com Inc. (“Voip-Pal”, Company”) (OTC Pink:VPLM) is pleased to announce on February 11, 2014, the United States Patent and Trademark Office (USPTO) updated its website to show Voip-Pal’s Uninterrupted Transmission for Internet Protocol (UI) patent application has been dispatched to the Final Data Capture (FDC) stage of the issue process and the application is considered “Ready for Issue.” According to the USPTO website, the average length of time an application spends in FDC is five weeks.
Sign-up for Voip-Pal.com Inc. Announces its Uninterrupted Transmission for Internet Protocol Patent Has Been Dispatched to Final Data Capture by the USPTO investment picks
2014/3/3
Voip-Pal.com Inc. (“Voip-Pal”, Company”) (OTC Pink: VPLM) is pleased to announce that they have received issue notification from the United States Patent and Trademark Office (USPTO) regarding the Company’s Uninterrupted Transmission of Internet Protocol Transmissions During Endpoint Changes (UI) patent.
Sign-up for Voip-Pal.com Inc.’s Patent Application for Uninterrupted Transmission for Internet Protocol Receives Issue Notification from the USPTO investment picks
2013/11/6
Boingo Wireless (NASDAQ: WIFI), the leading DAS and Wi-Fi provider that serves consumers, carriers and advertisers worldwide, today announced an agreement with Marine Corps Community Services (MCCS) that enables the company to provide Internet Protocol TV (IPTV) and broadband Internet services at all United States Marine Corps (USMC) bases worldwide.
Sign-up for Boingo Awarded U.S. Marine Corps On-Base Broadband Internet, Internet Protocol TV Contracts investment picks
2013/11/6
Boingo Wireless (NASDAQ: WIFI), the leading DAS and Wi-Fi provider that serves consumers, carriers and advertisers worldwide, today announced an agreement with The Army & Air Force Exchange Service to provide on-base broadband Internet and Internet Protocol TV (IPTV) services, starting at more than a dozen of the largest Army and Air Force bases in the continental United States.
Sign-up for Boingo Chosen to Provide Broadband Internet and Internet Protocol TV Service at U.S. Army and Air Force Sites investment picks
Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov , “Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass.” http://www.clinicaltrials.gov/ct2/show/NCT02025621?term=levosimendan&rank=12 Oxygen Biotherapeutics previously announced that it had selected Duke University’s Duke Clinical Research Institute (DCRI) to conduct the Phase 3 trial of the levosimendan.
Sign-up for Oxygen Biotherapeutics Announces Key Details of Phase 3 Trial Protocol for levosimendan investment picks
2014/2/11
Voip-Pal.com Inc. (“Voip-Pal”, “Company”) (OTC Pink: VPLM) is pleased to announce that the Company has received in hand the first four patents in its suite of technology.
Sign-up for Voip-Pal.Com Inc.’s Fifth and Final Patent Application for Uninterrupted Transmission for Internet Protocol Has Received a Corrected Notice of Allowability and is Awaiting Issuance as a Patent investment picks
2013/9/4
Teradici , the developer of the PCoIP ® protocol, and VMware, the global leader in virtualization and cloud infrastructure, today announced an extended partnership to continue collaboration on PCoIP development and innovation that will support next-generation virtual desktops from VMware.
Sign-up for Teradici and VMware Strengthen Partnership to Meet Increasing Demand for PCoIP Protocol and Zero Client Solutions investment picks
- PERSIST-2 trial expected to initiate in fourth quarter of 2013 - SEATTLE , Oct.
Sign-up for Cell Therapeutics Announces Agreement with the FDA on Special Protocol Assessment for Planned Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0905758001&sourceType=1 http://www.ccnmatthews.com/logos/20110201-biron200.jpg TORONTO, ONTARIO --
Sign-up for Black Iron Executes Protocol Agreement for Power and Confirmation Notice for Natural Gas Supply Securing Access to Existing Infrastructure investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0921954001&sourceType=1 http://www.ccnmatthews.com/logos/20110201-biron200.jpg TORONTO, ONTARIO --
Sign-up for Black Iron Secures Access to 20 Million Tonnes of Annual Rail Capacity With Executed Protocol Agreement investment picks
2014/2/11
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0926790001&sourceType=1 http://www.ccnmatthews.com/logos/20110201-biron200.jpg TORONTO, ONTARIO --
Sign-up for Black Iron Executes Protocol of Intent Agreements Securing Access to Water, Roads, Emergency Services and Telecom & Provides Update on Metinvest Transaction investment picks
2014/2/25
Maxim Integrated's Novato smart temperature-transmitter reference design transmits temperature measurement over -200-degree C to +850-degree C range with better than +0.1% accuracy.
Sign-up for Achieve Very Accurate Temperature Measurements Throughout Your Factory Using New 4-20mA Loop-Powered Temperature Transmitter with HART Protocol investment picks
2014/3/14
DURHAM, N.C., March 14, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) today issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients.
Sign-up for Chimerix Issues Statement Thanking the FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection investment picks
2014/3/17
CF102 has Orphan Drug Designation from U.S. FDA Global Liver Cancer Drug Market is Expected to Exceed $2 Billion by 2015 PETACH TIKVA, Israel , March 17, 2014 /PRNewswire/ --  Can-Fite BioPharma (TASE: CFBI), (NYSE MKT:CANF) , a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that a Phase II study protocol for the treatment of advanced liver cancer  with its CF102 has been approved by the Institutional Review Board (IRB) in Israel .
Sign-up for ‏Can-Fite: Phase II Study Protocol to Treat Patients with Advanced Liver Cancer with CF102 has been Approved by the IRB in Israel investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Research Protocol
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Proposals  |  Next: Research Providers